Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Cosmo Daisey who wrote (644)	5/5/1998 9:14:00 AM
From: Nero	Respond to of 2135

From Reuters: EntreMed Inc. (ENMD - news) is expected to extend its gains after jumping almost 40 points Monday on hopes the company is near a breakthrough on a treatment for cancer. EntreMed was up to 54 before the opening bell, from 51-13/16 at Monday's close. biz.yahoo.com

To: Cosmo Daisey who wrote (644)	5/5/1998 9:41:00 AM
From: Andreas Helke	Read Replies (1) \| Respond to of 2135

The tumors mentioned in the Nature paper were mouse tumors. They did not use naked mice but I don't know what mouse strain was actually used. Andreas

To: Cosmo Daisey who wrote (644)	5/5/1998 9:58:00 AM
From: Graham Dellaire	Read Replies (2) \| Respond to of 2135

Cosmo when this data first came out LAST YEAR, I asked around at the cancer intitute I work at. The consensus was even in human tumor implantation models weird things go on in the mouse. One treatement can work amazingly and then have almost no effect in man. Caution. But I feel endostatin and angiostatin may be different. THe fact they seem to have no side-effects and do not lead to drug resistance is very, very promising in any case. I repeat the stock is way ahead of itself. If you bought in the teens or lower sell, return when the stock hits the mid to low 20's. My opnion. But I was also into this stock last year at 10.5. Graham